Loading company…
Sapreme Technologies develops macromolecule therapeutics and technology for targeted biologics delivery.
Founded in 2016 and based in Bilthoven, Netherlands, Sapreme Technologies develops therapeutics and delivery technology for macromolecules. Its ENDOSCAPE platform is designed to help biologics reach intracellular targets with minimal toxicity; its work includes antibody-targeted antisense oligonucleotides for cancer and other indications. In October 2021, the company raised EUR 15 million in Series A funding led by Aglaia Oncology Funds to scale its platform and advance its drug pipeline.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in